Fennel Oil/Foeniculum vulgare / cycD1/CCND1 Cancer Research Results

FEO, Fennel Oil/Foeniculum vulgare: Click to Expand ⟱
Features:

fennel essential oil has major constituents commonly include trans-anethole, fenchone, estragole, limonene, and cis-anethole, and the proportions vary substantially by source, geography, and chemotype. One composition study found trans-anethole ranging 34.8–82.0%, fenchone 1.6–22.8%, estragole 2.4–17.0%, and limonene 0.8–16.5%. Another study found even wider variation, with estragole(toxic) reported up to 66% in some fennel oils.

Fennel Oil — Fennel oil is a volatile essential oil distilled mainly from the fruits or seeds of Foeniculum vulgare, with trans-anethole, fenchone, estragole, limonene, α-pinene, and related monoterpenes/phenylpropanoids as variable constituents. It is best classified as a phytochemical essential-oil mixture rather than a single-agent drug. Standard abbreviations include FEO, FVEO, and FVPEO when referring to Foeniculum vulgare subsp. piperitum essential oil. The oncology-relevant identity is highly chemotype-dependent: anethole-rich oils may show weak-to-moderate cytotoxic and anti-inflammatory effects, whereas estragole-rich oils introduce a major genotoxic-carcinogenic safety constraint.

Primary mechanisms (ranked):

  1. Essential-oil membrane perturbation and lipophilic cytotoxic stress, with weak-to-moderate cancer-cell growth inhibition at relatively high in-vitro concentrations.
  2. ROS-mediated stress signaling in sensitive cancer models, especially JNK/c-Jun, NRF2/HO-1/NQO1 stress-response activation, DNA damage signaling, p53-axis engagement, caspase-3 activation, PARP cleavage, and apoptosis.
  3. Cell-cycle arrest and apoptosis-marker modulation, including p53, caspase-3, Bcl-2, Ki-67, miR-21, and miR-92a in combination-oil models.
  4. Anti-inflammatory cytokine suppression in non-cancer models, including reduced IL-6, TNF-α, and IL-1β signaling; this is more relevant to normal-tissue inflammation than direct tumor cytotoxicity.
  5. TRPA1 agonism by trans-anethole, which is mechanistically clear but not yet a central validated anticancer mechanism for fennel oil.
  6. Estragole metabolic activation to DNA-reactive metabolites, a safety and carcinogenicity liability rather than a therapeutic anticancer mechanism.

Bioavailability / PK relevance: Fennel oil is a lipophilic volatile mixture with batch-dependent composition and uncertain systemic exposure after dietary or medicinal use. Oral systemic relevance is constrained by first-pass metabolism, variable absorption, tissue partitioning, and safety limits driven mainly by estragole content. Essential-oil composition should be specified before interpreting any mechanism claim.

In-vitro vs systemic exposure relevance: Common anticancer in-vitro concentrations are often high relative to plausible safe systemic exposures. Reported cytotoxic IC50 values for fennel oil are generally in the tens to hundreds of mg/L or µg/mL range, which should be treated as pharmacologically high and not directly translatable to oral use. This is concentration-driven and chemotype-dependent.

Clinical evidence status: Oncology evidence is preclinical only. Fennel oil has in-vitro cancer-cell cytotoxicity data and limited animal or extract-based anticancer evidence, but no established cancer RCT evidence and no regulatory approval as an anticancer therapy. Traditional medicinal use exists for non-oncology indications, but the essential oil has an unfavorable or constrained benefit-risk profile where estragole exposure is significant.

Fennel Oil Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Lipophilic membrane stress Viability ↓; membrane integrity ↓; morphology altered Potential membrane irritation at high exposure G Weak-to-moderate cytotoxicity Core essential-oil mechanism; requires high in-vitro concentrations and depends strongly on oil composition.
2 Mitochondrial ROS and oxidative stress signaling ROS ↑; JNK/c-Jun ↑; stress proteins ↑ Antioxidant or anti-inflammatory effects may occur in non-cancer models R/G Stress-amplified apoptosis Most convincing in TNBC cell data using Foeniculum vulgare subsp. piperitum oil; antioxidant rescue supports ROS involvement.
3 NRF2 stress-response activation NRF2 ↑; HO-1 ↑; NQO1 ↑ Potential cytoprotection ↑ (context-dependent) G Adaptive stress response plus apoptosis coupling In cancer cells, NRF2 activation appears secondary to ROS stress and coexists with apoptosis; not necessarily a purely protective effect.
4 p53 DNA damage apoptosis axis p53-axis ↑; γH2AX ↑; caspase-3 ↑; PARP cleavage ↑ Genotoxic-risk concern if estragole exposure is substantial G Apoptotic cell death Mechanistically relevant for anticancer interpretation, but safety interpretation is complicated by DNA-reactive estragole metabolism.
5 Cell-cycle and proliferation markers Cell-cycle arrest ↑; Ki-67 ↓; Bcl-2 ↓; miR-21 ↓; miR-92a ↓ Limited toxicity in tested lymphocytes in one oil-mixture model G Growth arrest and apoptosis Evidence is partly from fennel plus geranium oil mixtures, so attribution to fennel oil alone is uncertain.
6 Survivin mitochondrial apoptosis axis Survivin ↓; mitochondrial toxicity ↑; caspase-3 ↑ Normal liver-cell toxicity ↔ in seed-extract model G Apoptosis sensitization Relevant to Foeniculum vulgare seed extract rather than essential oil specifically; useful as genus-level support but not direct FEO evidence.
7 Inflammatory cytokine suppression Indirect tumor relevance only IL-6 ↓; TNF-α ↓; IL-1β ↓; inflammation ↓ G Anti-inflammatory modulation Better supported in normal inflammatory models than in tumor microenvironment models.
8 TRPA1 activation Unclear; context-dependent Ca²⁺ signaling possible TRPA1 ↑; sensory/neurogenic signaling possible R Ion-channel agonism Mechanistically specific for trans-anethole, but not yet a primary anticancer axis for fennel oil.
9 Estragole bioactivation and genotoxicity DNA adduct risk ↑; carcinogenic liability ↑ DNA-reactive metabolite risk ↑ G Safety constraint This is a negative translational feature. Estragole-rich oils should not be interpreted as desirable anticancer products.
10 Clinical Translation Constraint High in-vitro concentrations; chemotype heterogeneity; no oncology RCTs Estragole exposure, irritation, sensitization, pregnancy and pediatric constraints G Limits clinical relevance For database purposes, FEO should be marked preclinical and composition-dependent, with estragole content as a required safety note.

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
cycD1/CCND1, cyclin D1 pathway: Click to Expand ⟱
Source:
Type:
Also called CCND1 Gatekeeper of Cell-Cycle Commitment
The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression.
Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer.
Cyclin D1 is often found to be overexpressed in various cancers.
Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression.
Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer.
In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response.
Scientific Papers found: Click to Expand⟱
6396- ANE,  FEO,    Anethole Inhibits the Proliferation of Human Prostate Cancer Cells via Induction of Cell Cycle Arrest and Apoptosis
- in-vitro, Pca, PC3
TumCP↓, TumCG↓, TumCMig↓, CSCs↓, ROS↑, MPT↑, Casp3↑, Casp9↑, DNAdam↑, cl‑PARP↑, Bax:Bcl2↑, TumCCA↑, cycD1/CCND1↓, CDK4↓, cMyc↓, P21↑, p27↑, NF-kB↓, eff↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MPT↑, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,  

Cell Death ⓘ

Bax:Bcl2↑, 1,   Casp3↑, 1,   Casp9↑, 1,   p27↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 1,   P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   TumCG↓, 1,  

Migration ⓘ

TumCMig↓, 1,   TumCP↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  
Total Targets: 19

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: cycD1/CCND1, cyclin D1 pathway
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:404  Target#:73  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page